Tumour cell MMP3 expression was reported to be a prognostic factor for poor survival in breast cancer (Mehner et al., 2015), and MAP2 expression was shown to be significantly associated with pathological responses to neoadjuvant chemotherapy, regardless of breast cancer subtype (Kolacinska et al., 2012). This evidence concerns the gene MAP2 and neoplasm.